Jongen-Lavrencic M, et al. - In view of the high relapse rates among patients with acute myeloid leukemia (AML) following complete remission, the clinical value of next-generation sequencing for the prediction of relapse was determined. Detection of molecular minimal residual disease during complete remission had significant independent prognostic value with respect to relapse and survival rates among patients with AML; however, the detection of persistent mutations associated with clonal hematopoiesis did not have such prognostic value within a 4-year time frame.